Iranian Biomedical Journal
مجله بیومدیکال ایران
IBJ
Basic Sciences
http://ibj.pasteur.ac.ir
1
admin
1028-852X
2008-823X
-
10.61186/ibj
-
8888
-
en
jalali
1400
12
1
gregorian
2022
3
1
26
2
online
1
fulltext
en
Design of a Novel Recombinant Multi-Epitope Vaccine against Triple-Negative Breast Cancer
Molecular Immunology & Vaccines
Molecular Immunology & Vaccines
مقاله کامل
Full Length/Original Article
<strong>Background</strong>: Triple-negative breast cancer (TNBC) is determined by the absence of ERBB2, estrogen and progesterone receptors’ expression. Cancer vaccines, as the novel immunotherapy strategies, have emerged as promising tools for treating the advanced stage of TNBC. The aim of this study was to evaluate Carcinoembryonic antigen (CEA), Metadherin (MTDH), and Mucin 1 (MUC-1) proteins as vaccine candidates against TNBC.<br>
<strong>Methods</strong>: In this research, a novel vaccine was designed against TNBC by using different immunoinformatics and bioinformatics approaches. Effective immunodominant epitopes were chosen from three antigenic proteins, namely CEA, MTDH, and MUC-1. Recombinant TLR4 agonists were utilized as an adjuvant to stimulate immune responses. Following the selection of antigens and adjuvants, appropriate linkers were chosen to generate the final recombinant protein. To achieve an excellent 3D model, the best predicted 3D model was required to be refined and validated. To demonstrate whether the vaccine/TLR4 complex is stable or not, we performed docking analysis and dynamic molecular simulation.<br>
<strong>Result</strong>: Immunoinformatics and bioinformatics evaluations of the designed construct demonstrated that this vaccine candidate could effectively be used as a therapeutic armament against TNBC.<br>
<strong>Conclusion</strong>: Bioinformatics studies revealed that the designed vaccine has an acceptable quality. Investigating the effectiveness of this vaccine can be confirmed by supplementary <em>in vitro</em> and <em>in vivo</em> studies.
Adjuvants, Triple-negative breast cancer, Vaccine
160
174
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-4508-1&slc_lang=en&sid=1
Hassan
Dariushnejad
dariushnejad@gmail.com
100319475328460053954
100319475328460053954
No
Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
Vajihe
Ghorbanzadeh
vghorbanzadeh@gmail.com
100319475328460053955
100319475328460053955
No
Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
Soheila
Akbari
dr_akbari_s@yahoo.com
100319475328460053956
100319475328460053956
No
Department of Obstetrics and Gynecology, Lorestan University of Medical Sciences, Khorramabad, Iran
Pejman
Hashemzadeh
pejman7genetian@gmail.com
100319475328460053957
100319475328460053957
Yes
Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran